Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357989 · ClinicalTrials.gov registry record · Phase 3
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
A Phase 3 study, sponsored by Annovis Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 523
- Enrollment target
NCT05357989 is a Phase 3 study that has completed, run by Annovis Bio. The registered enrollment target is 523 participants.
The verdict
NCT05357989, a Phase 3 study, has completed, sponsored by Annovis Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 523 participants
- Enrollment target
Study Summary
The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: * The study duration will be up to 7-8 months. * The double-blind treatment duration will be up to 6 months. * There will be 5 in-clinic visits and 7 phone calls
Interventions
- DRUG Placebo
- DRUG buntanetap/posiphen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 523 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2023-12-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05357989
The ClinicalTrials.gov registry entry for NCT05357989 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 523 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annovis Bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05357989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05357989 about?
NCT05357989 is a clinical study titled "A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD". The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: * The study duration will be up to 7-8 months. * The double-blind treatment duration will be up to 6 months. * There will...
What is the current status of trial NCT05357989?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 523 participants. The study started on 2022-08-03. Estimated completion is 2023-12-04.
What interventions are being tested in trial NCT05357989?
The interventions under investigation include: Placebo (DRUG), buntanetap/posiphen (DRUG).
Who is sponsoring clinical trial NCT05357989?
This trial is sponsored by Annovis Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.